Untagged

Every year at Oxford PharmaGenesis, we select a charity so that we can make a donation in lieu of sending cards. This year, we are very pleased to support Evidence Aid, an organization that aims to inspire and enable those guiding the humanitarian sector to apply an evidence-based approach.

Oxford PharmaGenesis has recently become a mentor to a newly established patient group that aims to improve the lives of people affected by certain rare genetic disorders.

The theme of this year’s World Orphan Drug Congress (WODC) Europe was ‘strategy, advocacy and partnering for the world of orphan drugs and rare diseases’, which offered a great opportunity for Oxford PharmaGenesis to showcase our experience in the area of patient engagement.

Oxford PharmaGenesis were thrilled to be in Vienna earlier this month to take part in the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), which this year focused on ‘managing access to medical innovation: strengthening the methodology–policy nexus’.

Oxford PharmaGenesis insights into best practices for the planning and communication of real-world evidence (RWE) studies have been highlighted in an invited editorial, published online in the Journal of Comparative Effectiveness Research (http://www.futuremedicine.com/doi/full/10.2217/cer-2016-0070).

On 17–18 October, more than a hundred patients, patient advocates and representatives from pharma gathered in London, UK, for the 13th Annual eyeforpharma Patient Summit Europe to discuss the importance of patient centricity in the pharmaceutical industry.

Oxford PharmaGenesis was delighted to attend the Medical Affairs Leaders Forum in London, UK on 18–20 October. This meeting brought together medical affairs professionals and related industry staff and academics from Europe and beyond for 3 days of presentations, discussions and networking.

14­–17 September 2016, London, UK These are exciting times in the field of multiple sclerosis (MS) management; the past 5 years have seen an explosion in the number of disease-modifying therapies (DMTs) licensed for the treatment of patients with relapsing–remitting MS (RRMS).